As students go back to school and parents resign beach gear to its out-of-season digs at the back of the garage, Healio Dermatology reflects on big news from August on acne treatment, private equity in the marketplace and much more.
Continue reading for the top stories in dermatology from last month.
Hyperkalemia risk higher in older women taking spironolactone for acne
In women prescribed spironolactone for acne, the rate of incident hyperkalemia at follow-up was significantly higher in older patients, warranting further serum potassium monitoring guidance and protocols, according to findings from International Journal of Women’s Dermatology. Read more.
Private equity-backed groups acquiring more dermatology practices
One hundred eighty-four dermatology practices were acquired by private equity-backed groups from 2012 to 2018, with more acquisitions occurring over time and broadening in geographic reach, according to Sally Tan, MD, MPH, of the department of dermatology at Brigham and Women’s Hospital in Boston, and colleagues. Read more.
In a follow-up Q&A on private equity, Haley Beck, vice president on the investment team at Alpine Investors in San Francisco, spoke with Healio Dermatology about best practices to finding the right fit in a private equity partnership. Read more.
FDA accepts new drug application for tazarotene lotion for acne
The PDUFA action date is Dec. 22, and if approved, IDP-123 will be the first tazarotene acne treatment available in lotion form, the press release stated. Read more.
Aerosol sunscreen application density higher than lotion in practical use
“Based on our results, spray sunscreen may provide higher but still inadequate levels of UV protection than other sunscreen vehicles but with a considerable amount of waste,” Lindsey Broussard, MD, of the department of dermatology at the University of Colorado Anschutz Medical Campus, told Healio Dermatology. Read more.
Two topical psoriasis treatments now indicated in patients 12 years and older
The FDA has expanded the indicated patient population for Enstilar foam for topical treatment of plaque psoriasis to include patients aged 12 years and older. Leo Pharma also announced that Taclonex topical suspension has been approved for patients aged 12 years and older for plaque psoriasis of the body and scalp. Read more.